Why Goldman Sees Ionis Pharma Falling 40%
March 10, 2017 at 13:04 PM EST
With shares Ionis Pharmaceuticals ( IONS ) down more than 10% today, it looks like investors are taking Goldman Sachs ’s sell recommendation to heart. Analyst Salveen Richter downgraded Ionis from a neutral to a sell, calling the drug maker a “show me story." And Richter doesn't seem very optimistic abut Ionis's ability to "show me." A $25 price target implies a 40% downside for the stock.
